Clinical trial
Topical Squalamine in the Treatment of Retinal Neovascularization From Proliferative Diabetic Retinopathy
NCT01769183 is registered in ClinicalTrials.gov with Elman Retina Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Topical Squalamine in the Treatment of Retinal Neovascularization From Proliferative Diabetic Retinopathy
- Lead sponsor
- Elman Retina Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2013
- Completion date
- August 31, 2014
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.